BETA
Your AI-Trained Oncology Knowledge Connection!
Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC
A 5-year follow-up of the phase 3 EMPOWER-Lung 1 showed the greatest survival benefits in patients with NSCLC who have a PD-L1 expression of 90% or more.
Multicancer Early Detection Test Showed Clinical Benefit, Minimal Distress
Patients with a cancer signal detected via multicancer early detection test demonstrated similar results to those who did not in the PATHFINDER cohort study.
High-Dose Radiotherapy Boosts Survival Without Toxicity Increase in LS-SCLC
Phase 3 data support using twice-daily high-dose thoracic radiotherapy plus concurrent chemotherapy as an alternative therapy for patients with LS-SCLC.
Addressing Limitations to Clinical Trial Development for Lymphoma Treatment
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Bill Seeks to Require Reporting of Extravasated Tissue in Radiology
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Mindfulness/Activity Program May Ease Anxiety Over Death from Lung Cancer
End-of-life demands card game and mindfulness-based cancer recovery program use may enhance the quality of life for patients with lung cancer.
Consolidative Thoracic Radiotherapy Improves Survival in ES-SCLC
Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.
Classification System May Identify QOL Benefit with Palliative Radiotherapy
Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.
UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications
Results from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin with chemotherapy in relapsed/refractory multiple myeloma.
Optimizing Radiosurgery for CNS Tumors: Insights on Technology and Teamwork
William Kennedy, MD, discussed modern radiosurgery techniques, technology selection, and the multidisciplinary approach for treating complex CNS tumors.
Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC
Pooled results from the TRUST-I and TRUST-II trials showed that taletrectinib led to infrequent neurological TEAEs in patients with ROS1-positive NSCLC.
Landmark Radioligand Therapy Approval Bridges Treatment Gap in mCRPC
Administering 177Lu for mCRPC is a “team sport”, according to Steven Finkelstein, MD, DABR, FACRO.
3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma
Personalized therapeutic approaches and novel, targeted medicines can help patients with epithelial sarcoma attain better survival outcomes.
Elucidating the Clinical Landscape for Rare Lymphoma Treatment
Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.
Outlining Ongoing Clinical Developments in Treatment for Rare Lymphomas
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval
After the recent approval of 177Lu in PSMA+/mCPRCP prior to chemotherapy, Steven Finkelstein, MD, DABR, FACRO, highlights the importance of this milestone.
Bexmarilimab/Chemo Yield Positive Responses in Myelodysplastic Syndromes
Topline results from the phase 1/2 BEXMAB trial showed “one of the strongest data sets ever seen” in treatment-resistant higher-risk MDS populations.
Bria-IMT Enhances Survival vs Sacituzumab Govitecan in HR+ Breast Cancer
No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.
Addressing Racial Disparities, Social Barriers to Breast Cancer Care
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
3 Things You Should Know About Advances in Gastroesophageal Adenocarcinoma Therapy
Immunotherapy combinations and targeted therapy options may help bridge clinical gaps in early-stage, locally advanced, and metastatic gastroesophageal adenocarcinomas.
177Lu Marks Practice-Changing Approval in Metastatic CRPC
Steven Finkelstein, MD, DABR, FACRO, spoke about the impact of the approval of 177Lu for patients with PSMA-positive mCRPC.
Daratumumab Combo Earns EU Approval in Newly Diagnosed Multiple Myeloma
Data from the phase 3 CEPHEUS trial support the European Commission’s approval of the daratumumab-based regimen.
Tarlatamab Shows QOL, Symptom Benefits in Previously Treated SCLC
Patient-reported adverse effects associated with tarlatamab appeared to be generally mild in the phase 2 DeLLphi-301 trial.
sBLAs Submitted for Nogapendekin Alfa Inbakicept in Lymphopenia/NMIBC
In quarter 1 of 2025, nogapendekin alfa inbakicept received regenerative medicine advanced therapy designation for lymphopenia.
Preliminary TLX101 Results Show Promise in High-Grade Recurrent Glioma
Additional results from the phase 2 IPAX-Linz trial will be reported at the 2025 Nuclear Medicine and Neurooncology Symposium.
Synthetic Hypericin Achieves Treatment Success in Cutaneous T-Cell Lymphoma
At the indication of the FDA and EMA, the phase 3 FLASH2 trial will further evaluate synthetic hypericin in early-stage cutaneous T-cell lymphoma.
Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and Cancer
Human saliva may hold antioxidants that are able to monitor the oral cavity's oxidative processes and offer guidance for the development of new drugs.
Disparities in Treatment/Survival Outcomes Observed in Metastatic PDAC
Higher social vulnerability index was independently associated with lower odds of meeting at least one quality criterion in treatment for PDAC.
100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey
Adding Chemo to Radiotherapy Did Not Improve Survival Outcomes in Cervical Cancer
The addition of chemotherapy to radiotherapy did not show significant improvements in OS when compared with radiotherapy alone in patients with intermediate-risk cervical cancer.
